share_log

AIM ImmunoTech Says Phase 1 Study Shows its Intranasal COVID-19 Treatment Candidate Ampligen is Safe

AIM ImmunoTech Says Phase 1 Study Shows its Intranasal COVID-19 Treatment Candidate Ampligen is Safe

AIM免疫技術公司表示,第一階段研究顯示其鼻腔內新冠肺炎候選藥物安普利根是安全的
MT Newswires ·  2021/10/06 08:21

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論